CANF Stock Summary and Trading Ideas (Can Fite Biofarma | AMEX:CANF)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma trades on the AMEX stock market under the symbol CANF.

As of April 24, 2024, CANF stock price declined to $1.94 with 5,739 million shares trading.

CANF has a beta of 2.04, meaning it tends to be more sensitive to market movements. CANF has a correlation of 0.19 to the broad based SPY ETF.

CANF has a market cap of $9.68 million. This is considered a Sub-Micro Cap stock.

Last quarter Can Fite Biofarma reported $155,000 in Revenue and -$.01 earnings per share. This beat revenue expectation by $55,000 and exceeded earnings estimates by $.25.

In the last 3 years, CANF stock traded as high as $6.86 and as low as $.54.

CANF has underperformed the market in the last year with a price return of +10.2% while the SPY ETF gained +24.2%. CANF has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.0% and -14.2%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

CANF support price is $1.86 and resistance is $2.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CANF stock will trade within this expected range on the day.